Assessing diabetes risk in cirrhosis patients before and after liver transplant
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
This study is trying to find out what factors might lead to diabetes in adults with liver cirrhosis before and after they get a liver transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06950788 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify risk factors for developing diabetes in adult patients with cirrhosis who are being evaluated for liver transplantation. Participants will undergo various assessments, including continuous glucose monitoring, wrist actigraphy, and oral glucose tolerance tests, both prior to and following their liver transplant. The study will track these patients over a five-year period to evaluate the long-term outcomes related to diabetes development. The goal is to determine if specific laboratory and functional tests can predict the onset of diabetes after transplantation.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a diagnosis of cirrhosis who are being evaluated for liver transplantation.
Not a fit: Patients with a history of type 2 diabetes diagnosed more than five years ago will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at high risk for diabetes after liver transplantation, allowing for targeted interventions.
How similar studies have performed: While there have been studies on diabetes risk in transplant patients, this specific approach using advanced monitoring techniques is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients presenting to liver transplant clinic with a diagnosis of cirrhosis. * Age \>18 yrs. * Ability to understand and sign written consent form, or have a legally-authorized representative or proxy who can be approached for consent Exclusion Criteria: * Patients without consent * Patients with implantable cardioverter defibrillator devices or automated implantable cardioverter defibrillator devices will be excluded from the bio-electrical impedance analysis portion of the measurements. * Patients with unremovable electrical medical devices or devices that cannot turn off will be excluded from the bio-electrical impedance analysis measurements * Pregnant patients * Incarcerated patients * Patients with a history of type 2 diabetes mellitus diagnosed \> 5 years ago will be excluded from the Oral Glucose Tolerance Test portion of the study
Where this trial is running
Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Alan L Hutchison, MD PhD — University of Chicago
- Study coordinator: Alan L Hutchison, MD PhD
- Email: Alan.Hutchison@uchicagomedicine.org
- Phone: 773-702-1000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.